infusionsvätska

DRUG3 trials

Sponsors

Lipigon Pharmaceuticals AB, AstraZeneca AB, Toleranzia AB

Conditions

Heart failure with reduced ejection fractionModerate to severe hypertriglyceridemiaRenal impairmentgeneralised myasthenia gravis

Phase 1

A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)

CompletedCTIS2024-513143-82-00

AstraZeneca ABHeart failure with reduced ejection fraction, Renal impairment

Start: 2024-10-15End: 2025-08-21Target: 12Updated: 2025-02-11

A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

Not yet recruitingCTIS2024-515627-10-00

Toleranzia ABgeneralised myasthenia gravis

Target: 42Updated: 2025-02-12

Phase 2

A phase 2, randomised, double-blind, placebo-controlled trial to evaluate safety and local tolerability of four weekly administrations of A24110He in subjects with elevated triglyceride plasma concentrations

CompletedCTIS2023-509091-42-00

Lipigon Pharmaceuticals ABModerate to severe hypertriglyceridemia

Start: 2024-02-27End: 2026-01-08Target: 26Updated: 2025-07-04